Pretomanid - Global Alliance for TB Drug Development

Drug Profile

Pretomanid - Global Alliance for TB Drug Development

Alternative Names: PA 824

Latest Information Update: 03 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Global Alliance for TB Drug Development
  • Class 2 ring heterocyclic compounds; Antituberculars; Nitroimidazoles; Oxazines; Phenyl ethers; Small molecules
  • Mechanism of Action Cell wall inhibitors; Nitric oxide stimulants; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tuberculosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Tuberculosis

Most Recent Events

  • 16 Nov 2017 Global Alliance for TB Drug Development plans a phase IIc trial for Tuberculosis (Combination therapy) in August 2018 (NCT03338621)
  • 03 Jul 2017 Discontinued - Phase-I for Tuberculosis (Monotherapy, In volunteers) in USA (PO)
  • 27 Mar 2017 Global Alliance for TB Drug Development plans a phase III trial for Tuberculosis (Combination therapy) (NCT03086486)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top